Data / Form D filings / Ratio Therapeutics, Inc.
Ratio Therapeutics, Inc.: Form D filings
Ratio Therapeutics, Inc., a pharmaceuticals company in Boston, MA, filed 2 Form D notices with the SEC between 2023 and 2026. The latest, on July 31, 2026, reports $70 million sold of a $70 million offering to 57 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ONE DESIGN CENTER PLACE SUITE 19-601, Boston, MA, 02210
- Phone
- (617) 371-8898
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2004792
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | New notice | $69,999,974 | $69,999,974 | 57 | Jul 16, 2026 | sec.gov | |
| Dec 21, 2023 | New notice | $50,675,000 | $50,675,000 | 46 | Dec 7, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John W. Hoppin | Executive Officer, Director | |
| John Babich | Director | |
| Marc Becker | Executive Officer | |
| Scott MacDonald | Executive Officer | |
| William Cowan | Director | |
| Susan Whoriskey | Director | |
| Albert Holman | Director | |
| Allan Green | Director | |
| Brandon Ingersoll | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Jul 27, 2026 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Ratio Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.